TipRanks
Advertisement
Advertisement

DE:NOTA Stock Latest News

Novartis says remibrutinib showed comprehensive disease control in Phase 3 trial
The FlyNovartis says remibrutinib showed comprehensive disease control in Phase 3 trial
19h ago
NVS
Novartis announces results from six-year follow up study of Kisqali
PremiumThe Fly
Novartis announces results from six-year follow up study of Kisqali
23h ago
NVS
Novartis announces European Commission approval for Cosentyx in PMR
PremiumThe Fly
Novartis announces European Commission approval for Cosentyx in PMR
3d ago
NVS
Eloxx Pharmaceuticals appoints T.R. Srinivas as CMO
PremiumThe Fly
Eloxx Pharmaceuticals appoints T.R. Srinivas as CMO
4d ago
NVS
ELOX
Novartis treatment of idiopathic inflammatory myopathies gets orphan designation
PremiumThe Fly
Novartis treatment of idiopathic inflammatory myopathies gets orphan designation
5d ago
NVS
Novartis terminates mid-stage trial of lupus nephritis treatment, Endpoints says
PremiumThe FlyNovartis terminates mid-stage trial of lupus nephritis treatment, Endpoints says
8d ago
NVS
Novartis: Pipeline and Key Assets Seen Offsetting $20B Patent Headwind; Buy Rating Reiterated with Unchanged $150 Price Target
Premium
Ratings
Novartis: Pipeline and Key Assets Seen Offsetting $20B Patent Headwind; Buy Rating Reiterated with Unchanged $150 Price Target
12d ago
NVS
Novartis announces FDA approval of Rhapsido for symptomatic dermographism
Premium
The Fly
Novartis announces FDA approval of Rhapsido for symptomatic dermographism
17d ago
NVS
Novartis to present data from MS portfolio with 46 abstracts at MSToronto2026
PremiumThe Fly
Novartis to present data from MS portfolio with 46 abstracts at MSToronto2026
17d ago
NVS
Novartis price target lowered to $156 from $170 at Morgan Stanley
PremiumThe Fly
Novartis price target lowered to $156 from $170 at Morgan Stanley
18d ago
NVS
Novartis: Buy Rating Reaffirmed, Margin Outlook Strengthens with New Launches; Price Target Unchanged at CHF 150
PremiumRatings
Novartis: Buy Rating Reaffirmed, Margin Outlook Strengthens with New Launches; Price Target Unchanged at CHF 150
19d ago
NVS
Abogen announces licensing, option agreement with Novartis
PremiumThe Fly
Abogen announces licensing, option agreement with Novartis
22d ago
NVS
Piper confident Dyne’s Zeleciment rostudirsen will win January FDA approval
PremiumThe FlyPiper confident Dyne’s Zeleciment rostudirsen will win January FDA approval
25d ago
DYN
NVS
Nuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset
Premium
TipRanks Newswire
Nuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset
29d ago
AZN
NVS
Buy Rating Reiterated on Novartis as Diversified Pipeline Supports Medium-Term Growth; CHF 150 Price Target Unchanged
Premium
Ratings
Buy Rating Reiterated on Novartis as Diversified Pipeline Supports Medium-Term Growth; CHF 150 Price Target Unchanged
30d ago
NVS
Trump Trade: U.S. announces deal with Denmark over Greenland’s security
PremiumThe Fly
Trump Trade: U.S. announces deal with Denmark over Greenland’s security
1M ago
AZN
BMY
Novartis announces positive CHMP opinion for Cosentyx
PremiumThe Fly
Novartis announces positive CHMP opinion for Cosentyx
1M ago
NVS
U.S. weighs allowing most pharma licensing deals with China, Reuters says
PremiumThe Fly
U.S. weighs allowing most pharma licensing deals with China, Reuters says
1M ago
AZN
BMY
Legend Biotech appoints Ingrid Zhang as CEO
PremiumThe Fly
Legend Biotech appoints Ingrid Zhang as CEO
1M ago
NVS
LEGN
Buy/Sell: Wall Street’s top 10 stock calls this week
PremiumThe FlyBuy/Sell: Wall Street’s top 10 stock calls this week
1M ago
DYN
NKE
Midday Fly By: Oracle reports ‘beat and raise,’ Copart to buy ACV Auctions
Premium
The Fly
Midday Fly By: Oracle reports ‘beat and raise,’ Copart to buy ACV Auctions
1M ago
CL
GS
Novartis investors to increase scrutiny of company’s strategy, Reuters reports
Premium
The Fly
Novartis investors to increase scrutiny of company’s strategy, Reuters reports
1M ago
NVS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >